Literature DB >> 6604503

Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies.

J D Bos, H J Hulsebosch, S R Krieg, P M Bakker, R H Cormane.   

Abstract

Immunocompetent cells in exacerbating untreated psoriasis vulgaris skin lesions were immunophenotypically studied by the application of a selection of monoclonal antibodies in a two-stage immunoperoxidase technique. Epidermal changes include: focal accumulation of immunoglobulins in the stratum corneum, as demonstrated by a mixture of monoclonal anti-kappa and anti-lambda antibodies; focal accumulation of OKM-1 positive but Mo-2 negative cells high in the epidermis, reflecting granulocytes in Munro's abscesses; a marked decrease in epidermal Langerhans cells with focal abnormal clumping and smaller dendrites, as demonstrated by monoclonal anti-HLA-DR and anti-T6 (OKT-6) antibodies; and, sporadic exocytosis of mainly T1 (Leu-1), T8 (Leu-2a) positive suppressor/cytotoxic T lymphocytes. The dermal infiltrates were found to consist mainly of partically activated T1 (Leu-1), T4 (Leu-3a) positive T-helper/inducer cells with a smaller compartment of T1 (Leu-1), T8 (Leu-2a) positive suppressor/cytotoxic lymphocytes. These cells were found in close apposition to T6 (OKT-6), HLA-DR positive Langerhans cells and further accompanied by a minor compartment of OKM-1, Mo-2 positive monocytes. No B-cells or plasma cells could be demonstrated in the dermis. Natural killer cells were observed only incidentally. These results fit best with the hypothesis that psoriasis is a chronic inflammatory condition as a result of persistent stimulation of T cells by immunogen(s) of epidermal origin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6604503     DOI: 10.1007/bf00510050

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  24 in total

1.  [Monocytes in infiltrate of psoriatic lesions].

Authors:  M Hundeiker
Journal:  Dermatologica       Date:  1970

2.  Investigation on Langerhans cells in pathological human epidermis.

Authors:  P Lisi
Journal:  Acta Derm Venereol       Date:  1973       Impact factor: 4.437

3.  The dermal inflammatory reaction in initial psoriatic lesions.

Authors:  O Braun-Falco; C Schmoeckel
Journal:  Arch Dermatol Res       Date:  1977-03-25       Impact factor: 3.017

4.  Biosynthesis and processing of a human T lymphocyte antigen.

Authors:  Y Bergman; R Levy
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

5.  A monoclonal antibody reactive with human peripheral blood monocytes.

Authors:  J Breard; E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  J Immunol       Date:  1980-04       Impact factor: 5.422

6.  Reactivity of Langerhans cells with hybridoma antibody.

Authors:  E Fithian; P Kung; G Goldstein; M Rubenfeld; C Fenoglio; R Edelson
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

7.  Earliest clinical and histological changes in psoriasis.

Authors:  O Chowaniec; S Jabłońska; E H Beutner; M Proniewska; M Jarzabek-Chorzelska; G Rzesa
Journal:  Dermatologica       Date:  1981

8.  Functional and developmental compartments of human T lymphocytes.

Authors:  P C Kung; G Goldstein
Journal:  Vox Sang       Date:  1980-09       Impact factor: 2.144

9.  Antigens on human monocytes identified by monoclonal antibodies.

Authors:  R F Todd; L M Nadler; S F Schlossman
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

10.  Normal numbers of phenotypic helper, suppressor, and total T cell populations in psoriasis vulgaris: quantitation by monoclonal antibodies.

Authors:  W P DePietro; C L Berger; L C Harber; R L Edelson
Journal:  J Am Acad Dermatol       Date:  1981-09       Impact factor: 11.527

View more
  50 in total

1.  Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin.

Authors:  J D Bos; C Hagenaars; P K Das; S R Krieg; W J Voorn; M L Kapsenberg
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

2.  Elevated serum-soluble ELAM-1 levels in patients with severe plaque-type psoriasis.

Authors:  L Kowalzick; K Neuber; M Weichenthal; I Köhler; J Ring
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

3.  Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes.

Authors:  Z Bata-Csorgo; C Hammerberg; J J Voorhees; K D Cooper
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

Review 4.  Cytokine-based therapy in psoriasis.

Authors:  Anupam Mitra; Robyn S Fallen; Hermenio Cavalcante Lima
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

Review 5.  Immunology of psoriasis.

Authors:  Michelle A Lowes; Mayte Suárez-Fariñas; James G Krueger
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

6.  Scid mouse model of psoriasis: a unique tool for drug development of autoreactive T-cell and th-17 cell-mediated autoimmune diseases.

Authors:  Smriti K Raychaudhuri; Siba P Raychaudhuri
Journal:  Indian J Dermatol       Date:  2010 Apr-Jun       Impact factor: 1.494

7.  Targeting IL-23: insights into the pathogenesis and the treatment of psoriasis.

Authors:  Hermenio Cavalcante Lima; Alexandra Boer Kimball
Journal:  Indian J Dermatol       Date:  2010 Apr-Jun       Impact factor: 1.494

8.  Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.

Authors:  A Y Goedkoop; M C Kraan; M B M Teunissen; D I Picavet; M A de Rie; J D Bos; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

9.  Immunohistochemical analysis of sensory nerves and neuropeptides, and their contacts with mast cells in developing and mature psoriatic lesions.

Authors:  A Naukkarinen; I Harvima; K Paukkonen; M L Aalto; M Horsmanheimo
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

10.  Ustekinumab in the therapy of chronic plaque psoriasis.

Authors:  Jenna L O'Neill; Robert E Kalb
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.